Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Sees Significant Decrease in Short Interest

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 142,536 shares, a decline of 36.8% from the May 31st total of 225,427 shares. Based on an average trading volume of 897,604 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

Coloplast A/S Price Performance

OTCMKTS CLPBY opened at $6.04 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.09 and a debt-to-equity ratio of 1.66. Coloplast A/S has a 12 month low of $5.64 and a 12 month high of $10.03. The stock has a market cap of $13.61 billion, a price-to-earnings ratio of 43.14, a PEG ratio of 1.83 and a beta of 0.22. The company’s 50 day moving average is $6.11 and its two-hundred day moving average is $7.17.

Get Coloplast A/S alerts:

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a net margin of 7.46% and a return on equity of 33.15%. As a group, research analysts anticipate that Coloplast A/S will post 0.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CLPBY shares. The Goldman Sachs Group downgraded shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold”.

View Our Latest Report on Coloplast A/S

Coloplast A/S Company Profile

(Get Free Report)

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

Recommended Stories

• Five stocks we like better than Coloplast A/S
• Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
• Why Kroger’s Giant Eagle Deal Could Change Everything
• Why the Comcast Spin-Off Won’t Fix What’s Actually Broken
• Shorting the Grid: Bloom Energy’s $25B AI Power Play

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.